# OnCo record braf (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/braf/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "braf" ;
  schema:name "BRAF"@en ;
  schema:description "BRAF is a signalling kinase mutated in half of melanomas; blocking it with two drugs at once became a template for targeted therapy."@en ;
  schema:url <https://onco.cc/targets/braf/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/BRAF_(gene)>, <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157764>, <https://www.uniprot.org/uniprotkb/P15056/entry>, <https://www.ncbi.nlm.nih.gov/gene/673> ;
  owl:sameAs <http://www.wikidata.org/entity/Q17853226> ;
  schema:citation <https://en.wikipedia.org/wiki/BRAF_(gene)> ;
  onco:tag "driver", "kinase" ;
  schema:alternateName "BRAF" ;
  onco:targetClass "kinase" ;
  onco:firstDescribed "1988"^^xsd:gYear ;
  onco:related <https://onco.cc/biomarkers/braf-v600e/>, <https://onco.cc/biomarkers/braf-class-ii-iii/>, <https://onco.cc/biomarkers/braf-fusion/> ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/thyroid/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/gallbladder/> ;
  onco:drugs <https://onco.cc/drugs/guardant360-cdx/>, <https://onco.cc/drugs/oncomine-dx-target-test/>, <https://onco.cc/drugs/therascreen-cdx/>, <https://onco.cc/drugs/gc101-til/> ;
  onco:companies <https://onco.cc/companies/imagene-ai/>, <https://onco.cc/companies/nested-therapeutics/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/colorectal-cancer-signalling/>, <https://onco.cc/pathways/glioma-signalling/>, <https://onco.cc/pathways/melanoma-signalling/>, <https://onco.cc/pathways/pancreatic-cancer-signalling/>, <https://onco.cc/pathways/thyroid-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/sidedness/>, <https://onco.cc/terms/braf-v600-mutation/> ;
  onco:trials <https://onco.cc/trials/nct05503797/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-witkiewicz-pancreatic-exomes-utsw-nat-commun-2015/>, <https://onco.cc/key-papers/paper-philip-kras-wild-type-pancreatic-ccr-2022/>, <https://onco.cc/key-papers/paper-aguirre-real-time-genomic-characterisation-pancreatic-cancer-discov-2018/>, <https://onco.cc/key-papers/paper-venderbosch-mmr-braf-metastatic-colorectal-pooled-ccr-2014/>, <https://onco.cc/key-papers/paper-loree-tumour-location-continuum-colorectal-ccr-2018/>, <https://onco.cc/key-papers/paper-kopetz-beacon-encorafenib-braf-colorectal-nejm-2019/>, <https://onco.cc/key-papers/paper-breakwater-nejm-2025/>, <https://onco.cc/key-papers/paper-jones-non-v600-braf-colorectal-jco-2017/>, <https://onco.cc/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/> .